Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

MRNA vs SYRE: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MRNA Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 6–4 Matrix Metrics)

MRNA Overall Winner 6-Pillar Tally: MRNA 5 – 1 SYRE Matrix Metrics: MRNA 6 – 4 SYRE

As of Nov 16, 2026, Moderna, Inc. (MRNA) is the stronger overall head-to-head candidate over Spyre Therapeutics, Inc. (SYRE) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). MRNA carries a Unified Composite Score of 46.8/100 (HOLD) at $215.96 (23.0x Forward P/E, -80.8% operating margin), whereas SYRE carries 44.4/100 (HOLD) at $99.97 (N/M Forward P/E, 0.0% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MRNA vs SYRE
MRNA NASDAQ Head-to-Head Winner
Moderna, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$215.96
-3.32% 1D
Market Cap $93.6B
TTM Revenue $2.52B
Forward P/E 23.0x
Beta / 30D Vol 2.35β · 101% Vol
Unified Composite Score
46.8 / 100 HOLD
Tech 41.0 Fund 50.0 Flow 67.0 Mom 41.1
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 48
RSI-14: 47.5 · SMA20: $229.93 · SMA50: $203.07
SYRE NASDAQ
Spyre Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$99.97
-3.88% 1D
Market Cap $9.8B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.75β · 59% Vol
Unified Composite Score
44.4 / 100 HOLD
Tech 31.0 Fund 33.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 54
RSI-14: 53.5 · SMA20: $98.78 · SMA50: $91.70

6-Pillar Scorecard Institutional Category Breakdown (MRNA 5 – 1 SYRE)

Columns: Metric · MRNA · SYRE
1. Valuation Multiples MRNA
Forward P/E 23.0x N/M
Trailing P/E 23.0x N/M
PEG Ratio N/M N/M
EV / Revenue 38.3x N/M
2. Growth & Scale MRNA
Revenue Growth (YoY) +29.2% +0.0%
Earnings Growth (YoY) -85.1% -99.7%
TTM Revenue (USD) $2.52B N/A
Market Cap $93.6B $9.8B
3. Profitability & Quality SYRE
Gross Margin -42.0% N/A
Operating Margin -80.8% 0.0%
Net Profit Margin -110.5% 0.0%
Return on Equity (ROE) -34.5% -35.0%
4. Balance Sheet & Cash Flow MRNA
Cash Generation (TTM) -$2.04B N/A
Cash Flow Margin -81.0% N/A
Net Cash / Leverage $3.03B Net Debt (0.62x D/E) $10.06 Book/Sh · -35.0% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MRNA
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 70.5% (30th %ile) 87.9% (10th %ile)
Put/Call OI Skew 1.12x (Balanced) N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat MRNA
OpEx & R&D Intensity 38.8% of Rev ($980M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MRNA (6) vs SYRE (4)
Institutional Metric MRNA SYRE Criterion Row Edge
Market Capitalization
Scale
$93.6B $9.8B Larger Scale MRNA
Trailing P/E Ratio
Valuation
23.0x N/M Lower Multiple MRNA
Forward P/E Ratio
Valuation
23.0x N/M Lower Multiple MRNA
Revenue Growth (YoY)
Growth
+29.2% +0.0% Higher Growth MRNA
Operating Margin (TTM)
Profitability
-80.8% 0.0% Higher Margin SYRE
Net Profit Margin
Profitability
-110.5% 0.0% Higher Margin SYRE
Return on Equity (ROE)
Capital Efficiency
-34.5% -35.0% Higher ROE MRNA
52-Week Range Position
Momentum
75% ($22–$281) 88% ($22–$111) Stronger Trend SYRE
Beta / 30D Volatility
Risk Regime
2.35β · 101% Vol 1.75β · 59% Vol Lower Realized Risk SYRE
Unified Institutional Score
Composite Signal
46.8 / 100 (HOLD) 44.4 / 100 (HOLD) Higher Composite MRNA
Trailing 12M Revenue (USD)
Operating Scale
$2.52B N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-42.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 38.3x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$2.04B ($3.03B Net Debt (0.62x D/E)) N/A ($10.06 Book/Sh · -35.0% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SYRE +26.05 pp
MRNA: -0.94% · SYRE: +25.11%
3M Horizon MRNA +250.29 pp
MRNA: +243.0% · SYRE: -7.29%
6M Horizon MRNA +306.24 pp
MRNA: +348.88% · SYRE: +42.64%
1Y Horizon MRNA +423.46 pp
MRNA: +765.2% · SYRE: +341.74%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MRNA vs SYRE. Trailing 12-month operating profitability (MRNA -80.8% vs SYRE 0.0%) and valuation multiples (MRNA 23.0x vs SYRE N/M Forward P/E) are benchmarked directly in Pillar 4 below.

MRNA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$2.52B
Gross Margin-42.0%
Op. Margin-80.8%
ROE / Fwd P/E-34.5% · 23.0x
SYRE ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-35.0% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MRNA CONSOLIDATION
18d in phase · OBV NEUTRAL
Current IV 70.5%
IV Percentile 30th %ile
Put/Call OI Skew 1.12x (Balanced)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MRNA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SYRE UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 87.9%
IV Percentile 10th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SYRE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MRNA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $93.6B market capitalization and -80.8% operating margin.
OpEx & R&D Reinvestment 38.8% of Rev ($980M)
90D Engineering Disclosures 0 Published · mRNA Therapeutics
SYRE Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $9.8B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ MRNA vs SYRE Key Questions & Quantitative Answers

As of Nov 16, 2026, Moderna, Inc. (MRNA) is the stronger overall head-to-head candidate over Spyre Therapeutics, Inc. (SYRE) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). MRNA carries a Unified Composite Score of 46.8/100 (HOLD) at $215.96 (23.0x Forward P/E, -80.8% operating margin), whereas SYRE carries 44.4/100 (HOLD) at $99.97 (N/M Forward P/E, 0.0% operating margin). Technically, MRNA sits in a Neutral phase (RSI 47.5, CONSOLIDATION options structure) and SYRE sits in a Neutral phase (RSI 53.5, UNCLASSIFIED options structure).

MRNA leads the Growth & Scale pillar: MRNA posts +29.2% YoY revenue growth and -85.1% YoY earnings growth on $2.52B TTM revenue (-42.0% gross margin, -80.8% operating margin), compared with SYRE at +0.0% YoY revenue growth and -99.7% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, MRNA generates $2.52B in USD-normalized revenue versus N/A for SYRE. In operating R&D and SG&A reinvestment, MRNA deploys 38.8% of Rev ($980M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SYRE.

MRNA screens cheaper on headline valuation multiples. MRNA trades at 23.0x Forward P/E, 23.0x Trailing P/E, N/M PEG, and 38.3x EV/Revenue (-81.0% FCF margin), whereas SYRE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MRNA (-34.5% ROE) versus SYRE (-35.0% ROE) capital efficiency.

In options market volatility and institutional positioning, MRNA carries 70.5% implied volatility (30th %ile, Balanced (25th–60th %ile)), a 1.12x (Balanced) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (2.35β · 101% Vol realized risk). By comparison, SYRE carries 87.9% implied volatility (10th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.75β · 59% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.